Scienture Holdings (SCNX) Fair Value & Analysis
Healthcare · US · Market cap $15.5M
Scienture Holdings
SCNX · US
Fair value as of: Jul 21, 2026
From 3 valuation models · updated today
Share price +8.9% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.2410 – $2.60 · fair‑value band $0.2878 – $0.4794 · the $0.4160 price screens above the $0.3836 fair value. As of Jul 21, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Scienture Holdings (SCNX) currently trades at $0.4160, while our model-based Fair Value estimate is $0.3836, implying the stock looks roughly 7.8% fairly valued today. We read business quality at 19/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $478K. It earns a return on equity of -56.6%. The balance sheet holds a net cash position of $6.6M. Fundamentals as of Jul 21, 2026
Our scenario range runs from $0.2878 (bear case) to $0.4794 (bull case); at $0.4160, the current price sits within that range. For context, the median of 10 Healthcare peers we cover trades at 23% fair-value upside, at -8%, SCNX screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 21, 2026. TTM = trailing twelve months.
About the company
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Scienture Holdings reported revenue of $432K in FY2025 versus $9.9M in FY2021, a compound −54.3%/yr. Reported net income was −$41.5M in FY2025.
Is SCNX fairly valued? → Check now
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc JDHIY | $4.55 | $8.78 | +93% |
| Alibaba Health Information Technology Limited ALBBY | $8.42 | $6.94 | -18% |
| Raia Drogasil S.A RADL3 | R$17.46 | R$16.13 | -8% |
| Yifeng Pharmacy Chain Co 603939 | ¥20.91 | ¥22.00 | +5% |
| Clicks Group CLCGY | $27.97 | $34.29 | +23% |
| Sugi Holdings SGIPF | $16.29 | $64.34 | +295% |
| Corporativo Fragua, S.A. CGSBF | $29.66 | $29.34 | -1% |
| DaShenLin Pharmaceutical Group 603233 | ¥15.87 | ¥23.86 | +50% |
| Redcare Pharmacy NV RDC | €48.26 | €124.16 | +157% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥11.74 | ¥11.45 | -2% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Scienture Holdings (SCNX) undervalued?
What is the fair value of SCNX?
What is the quality score of SCNX?
What is the revenue of Scienture Holdings (SCNX)?
What is the net profit margin of SCNX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Scienture Holdings analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.